German technology group Schott has invested an additional double-digit million-Euro figure into a new glass tank at its tubing manufacturing plant in Jambusar, India.
The expansion follows recent investments at the site, which included the construction of an additional tank facility last year. Production of pharmaceutical Fiolax tubing from the new tank is scheduled to begin in the second half of 2020. The capacity expansion is part of the company’s global growth strategy of its pharma tubing and packaging business segments.
Dr. Patrick Markschlaeger, Executive Vice President at Schott, Business Unit Tubing, said: “The pharmaceutical market is booming worldwide with a very high demand for premium pharmaceutical packaging and tubing. “In order to supply the rapidly growing domestic and Asian market, we are investing once again a multimillion-euro figure in our Jambusar site to increase our manufacturing capacity in India.”
Fiolax borosilicate glass tubing is said to feature a high hydrolytic resistance. Sundeep Prabhu, Vice President Sales & Marketing Jambusar at Schott Glass Pvt. India added: “Since its development in 1911, Fiolax has been established as the gold-standard material for pharmaceutical containers and its behaviour with drugs is well researched and proven. In India, it is primarily used to manufacture glass vials and ampoules.”
In line with the company’s aim to manufacture zero defect tubing, the tank will feature the big data approach perfeXion. The process, which was rolled-out globally by Schott in 2017, reportedly ensures 100% quality control of each tube on the line by using cameras, laser and IR inspection systems. “In Jambusar, we are combining Indian and European technologies and local skills. With the additional tank, we are also adding new workplaces,” explained Georg Sparschuh, Managing Director at Schott Glass India Pvt. India. Along with the tank facility, the investment includes an extension of the batch house, warehouses and a new chimney.
04.07.2019, Schott AG
News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.